Rallybio Return on Equity

Rallybio (RLYB) currently reports a ROE of 48.2%. That is above the Healthcare sector average of 22.76%. Use the charts on this page to explore Rallybio's ROE history and peer comparisons.

Rallybio's ROE of 48.2% is higher than the Healthcare sector average of 22.76%. That is roughly 111.8% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Rallybio's current 48.2% should be judged against Healthcare norms (sector average: 22.76%) and against RLYB's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 48.2%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.76%. From there, open related valuation or income-statement pages for Rallybio, and consider following RLYB for alerts when major investors trade the stock.

Rallybio is classified in the Healthcare sector. On ROE, it currently shows 48.2% versus a sector average near 22.76%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RLYB with unrelated industries.